-+ 0.00%
-+ 0.00%
-+ 0.00%

BetterLife Pharma's BETR-001 Shows Neuroplasticity-Related Effects in Mouse Study

PUBT·11/17/2026 13:15:50
Listen to the news
BetterLife Pharma's BETR-001 Shows Neuroplasticity-Related Effects in Mouse Study
  • BetterLife Pharma announced preclinical mouse research showing BETR-001 produced gene-expression changes linked to brain plasticity that broadly overlapped with LSD’s effects.
  • Results will be presented November 17, 2026, at Neuroscience 2026 in Washington, D.C.
  • BETR-001 showed a non-hallucinogenic behavioral profile in earlier mouse studies.
  • Clinical development is planned for 2027, targeting chronic cluster headache and chronic migraine.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BetterLife Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170815PRIMZONEFULLFEED9879297) on November 17, 2026, and is solely responsible for the information contained therein.